Circulating Tumor DNA-based Minimal Residual Disease Detection in Colorectal Cancer Management : Episode 4
Describing the Value of ctDNA in Clinical Practice
The key opinion leaders share their approaches for communicating about circulating tumor DNA and minimal residual disease to patients, emphasizing the significance of ctDNA testing in detecting MRD.
- Mackenzie Phillips: How do you describe ctDNA and MRD to patients?
- Jing Yi: Why do you think it’s important to do ctDNA testing for MRD?
Recent Videos
Related Content
FDA Approves Encorafenib/Cetuximab Plus mFOLFOX6 for Advanced BRAF V600E+ CRC
December 20th 2024Article
The FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.
